I'm working in...
Arrow for button
Cross Arrow

I'm working in...

Role
Company
Select

How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle?

Diane Lacroix, Vice President – Clinical Data Management, eClinical Solutions

Modern clinical trials face significant challenges, from trial design to operational intricacies and data management. Technology and scientific innovation have made it easier to collect increasing amounts of data, but this not only places critical burdens on patients and sites — it complicates the data operations of research. Biometrics teams must now possess technical skills, therapeutic-area-specific data expertise, and an adaptable mindset to navigate this data-heavy environment. Traditional full-service outsourcing models often downplay the priority of data in trials and lack the flexibility required for complex, data-driven studies.

Biopharma companies are more focused than ever on data as the critical asset of their studies and organization. As a result, sponsors are emphasizing several key priorities in their outsourced strategies: efficient management of data complexity, the ability to leverage technological advancements, and a move beyond operational execution to technology optimization (including adoption of AI and risk-informed approaches).

Outsourcing partners offering domain and function expertise around clinical data can address sponsors’ priorities to streamline data operations. This reshaping of a data-focused outsourcing strategy addresses widespread trial efficiency needs while helping life sciences organizations advance toward a comprehensive clinical data science framework, establish the foundation for AI-enabled productivity, and gain study and program-wide effectiveness.

Read the full article.


By submitting, you agree to the processing of your personal data by eClinical Solutions as described in our Privacy Policy.